Clinical Trial Update: Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating fecal loss of vedolizumab and its impact on serum drug levels, outcomes, and response in ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Guy's and St Thomas' NHS Foundation Trust | Conditions: Ulcerative Colitis | Phase 4 | Status: UNKNOWN